RxDoctor Payments Data

Reid Holly

Psychiatric/Mental Health · Oxford, MSNPI 1407576382

Payments from drug & device makers

$1,215in general payments, 2019–2025

Across 59 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$176
  • Otsuka America Pharmaceutical, Inc.$172
  • Takeda Pharmaceuticals U.S.A., Inc.$168
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130
  • Supernus Pharmaceuticals, Inc.$104
  • Tris Pharma Inc$91
  • plus $375 from 11 others

What the payments were for

  • Food & beverage$1,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,215 in reported general payments places this provider in the 60th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$8,066
Medicare patients
19
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate12$18,493
RexultiBrexpiprazole12$17,373
Tranylcypromine Sulfate12$865
Buspirone Hcl28$591
Propranolol Hcl50$524
Quetiapine Fumarate69$441
Fluoxetine Hcl27$367
Alprazolam25$316
Prazosin Hcl17$315
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$250
Duloxetine Hcl14$246
Trazodone Hcl29$220
Fluvoxamine Maleate13$187
Lamotrigine16$138
Bupropion Hcl SrBupropion Hcl29$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$130$18,49312 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$17,37312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →